Journal of Clinical Oncology.
Schedule your weight loss consultation today and well help you choose the right option for your goals and budget
Emerging evidence demonstrates that GLP-1 receptor agonists may provide significant benefits for liver health, particularly in patients with metabolic dysfunction-associated steatotic liver disease (MASLD, formerly known as non-alcoholic fatty liver disease or NAFLD) and its inflammatory subtype, metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH)
A lot of these people dont need to be on these medicines. This article first appeared in The Checkup, MIT Technology Reviews weekly biotech newsletter
Losing weight can feel like an uphill battle
In the UK, SCoMIS has been announced in 2025, a landmark government-funded and IQVIA-run study will enrol thousands of patients, including those from Scotlands most deprived areas, to assess the impact of obesity treatments in real-world settings